In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • To me, Cancer Commons has not only been a great resource but I feel the people I’ve dealt with are my friends. They give me a great sense of comfort. My questions and concerns are always addressed very promptly. I would highly recommend Cancer Commons.

    Wife of glioblastoma patient

  • I am grateful for the concise and accurate summary of my treatment options. I have been waiting 3 years for this. Your goal to close the gap between metastatic trials and patients holds great promise to speed up success.

    Michelle Kendall
    Cancer patient

  • In a field as complex and dynamic as molecular oncology in 2020, Cancer Commons offers an amazing opportunity for patients with advanced cancer to obtain scientifically up-to-date additional options that may improve both the length and quality of their lives, all free of charge.

    Gavin Gordon, PhD
    Molecular Pathologist

  • When you’re completely overwhelmed by a glioblastoma diagnosis, it is quite miraculous to find Cancer Commons. Having a second opinion and someone to answer questions when we weren’t able to understand our doctor was very comforting. My husband’s tumor is currently stable, but we know where to turn if things change. Thank you!!

    Chris Bird
    Wife of a cancer patient

  • Cancer Commons is truly unique at rapidly matching patients with advanced cancer with the best precision therapy or clinical trial.

    E. David Crawford, MD
    Cancer Commons Advisor

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.